Core Viewpoint - Investors in Varonis Systems, Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged misleading statements regarding the company's ability to sustain its annual recurring revenue (ARR) growth trajectory [1][2]. Group 1: Lawsuit Details - The lawsuit alleges that from February 4, 2025, to October 28, 2025, Varonis failed to disclose its inability to maintain a high rate of quarterly conversions necessary for continued ARR growth [2]. - Defendants' positive statements about Varonis' business operations and prospects were claimed to be materially misleading and lacked a reasonable basis during the relevant period [2]. Group 2: Participation Information - Investors who suffered losses related to Varonis Systems, Inc. are encouraged to participate in the ongoing securities fraud lawsuit, with a lead plaintiff deadline set for March 9, 2026 [2]. - Interested parties can contact the Law Offices of Frank R. Cruz for more information or to participate in the class action [3][4].

CoreWeave securities between March 28, 2025, and December 15, 2025, inclusive (the "Class Period†). The lead plaintiff deadline is March 13, 2026. The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) CoreWeave had overstated the company's ability to meet customer demand for its service; (2) CoreWeave materially understated the scope and severity of the risk that CoreWeave's reliance on a single third-party data cent ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming March 9, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Ardent Health, Inc. ("Ardent†or the "Company†) (NYSE: ARDT) securities between July 18, 2024 and November 12, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ARDENT HEALTH, INC. (ARDT), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURI ...

NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against CoreWeave, Inc. (NASDAQ: CRWV) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired CoreWeave securities between March 28, 2025 and December 15, 2025, both dat ...

Core Viewpoint - A securities class action lawsuit has been filed against Varonis Systems, Inc. for alleged investment losses incurred by investors who purchased or acquired Varonis common stock between February 4, 2025, and October 28, 2025 [1][6]. Group 1: Lawsuit Details - The lawsuit claims that Varonis made false and misleading statements and failed to disclose critical information regarding its ability to sustain its Annual Recurring Revenue (ARR) growth without maintaining a high rate of quarterly conversions [2]. - The lead plaintiff deadline for the lawsuit is set for March 9, 2026, allowing affected investors to seek representation [3][6]. Group 2: Legal Representation - Kessler Topaz Meltzer & Check, LLP is the law firm representing the class of investors and encourages those who suffered significant losses to contact them for more information [4][5]. - The firm has a strong reputation in securities-fraud class actions and has achieved notable recoveries in past litigations [5]. Group 3: Affected Investors - The class period for the lawsuit is defined as February 4, 2025, through October 28, 2025, during which investors are seeking recovery for material misstatements and omissions [6]. - Investors can choose to be appointed as lead plaintiffs or remain absent class members, with the ability to share in any recovery not affected by their decision [3].

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Five Below, Inc. [1] Group 1: Legal Actions and Shareholder Rights - Long-term shareholders of Five Below may seek corporate governance reforms, return of funds, financial incentive awards, or other benefits [2] - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees [2] Group 2: Importance of Shareholder Participation - Shareholder involvement is crucial for improving company policies and practices, leading to enhanced transparency, accountability, and management effectiveness [3] Group 3: Firm's Background and Achievements - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [4]

Group 1 - A class action lawsuit has been filed against SLM Corporation (Sallie Mae) on behalf of investors who acquired its securities between July 25, 2025, and August 14, 2025 [1][2] - The lawsuit alleges that Sallie Mae concealed a significant increase in loan delinquencies and misrepresented the reasons for this increase, claiming that early-stage delinquencies were rising significantly despite the company's assertions that such increases were seasonal and manageable [3] - A report from TD Cowen on August 14, 2025, revealed that July delinquencies had increased by 49 basis points month-over-month, leading to an 8.09% decline in Sallie Mae's stock price, which fell by $2.67 to $30.32 on August 15, 2025 [4] Group 2 - Investors who purchased Sallie Mae securities during the class period have until February 17, 2026, to seek appointment as lead plaintiff representatives [2] - Berger Montague, the law firm handling the case, is recognized for its expertise in complex civil litigation and has recovered over $50 billion for clients over its 55-year history [6]

Group 1 - Trip.com Group Limited has received a notice of investigation from the State Administration for Market Regulations of China regarding potential violations of the Anti-Monopoly Law [2] - Following the announcement of the investigation, Trip.com's American Depositary Shares (ADS) experienced a decline of over 17% [2] - Kehoe Law Firm is investigating potential securities fraud claims on behalf of investors of Trip.com [1][2] Group 2 - Kehoe Law Firm is a nationally recognized firm that focuses on protecting investors from fraud and misconduct, having recovered over $10 billion for clients [4] - The firm litigates various issues including securities fraud, fiduciary breaches, and antitrust violations [5]

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly making misleading statements and failing to disclose material adverse facts regarding its business performance during the specified class period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Integer securities from July 25, 2024, to October 22, 2025 [1][2]. - Investors have until February 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against the Company - The complaint alleges that Integer overstated its competitive position and did not adequately disclose sales deterioration in its electrophysiology devices [3]. - The lawsuit claims that the company mischaracterized its growth drivers [3]. - The truth about the company's performance began to emerge on October 23, 2025, when it reduced its sales guidance, leading to a stock price decline of $35.22 per share, a drop of over 32% in one trading day [3].

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy and commercial prospects of its lead product candidate, nimacimab, during the specified Class Period [1][3]. Company Overview - Skye Bioscience, Inc. is a San Diego-based biotech company focused on developing therapies for obesity and metabolic diseases [2]. Legal Action Details - The lawsuit is on behalf of investors who acquired Skye securities from November 4, 2024, to October 3, 2025, and they have until January 16, 2026, to seek appointment as lead plaintiff [1][2]. - The complaint alleges that the company overstated the efficacy of nimacimab and exaggerated its clinical success and commercial potential [3]. Financial Impact - Following the release of topline results from the 26-week Phase 2a CBeyond study on October 6, 2025, which indicated that nimacimab did not meet its primary weight-loss endpoint compared to placebo, Skye's share price plummeted by 60%, falling from $4.75 to $1.90 per share [4].